Product Description
for investigation in patients with Multiple Sclerosis (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01031199)
Mechanisms of Action: BZD Agonist
Novel Mechanism: Yes
Modality: N/A
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Alzheimer Disease|Multiple Sclerosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT01035164 | P1 |
Completed |
Alzheimer Disease |
2010-01-01 |
|
NCT01031199 | P1 |
Completed |
Multiple Sclerosis |
2009-12-01 |